These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 28741234)

  • 1. Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature: Response to Comment.
    Dufrost V; Risse J; Wahl D; Zuily S
    Curr Rheumatol Rep; 2017 Aug; 19(8):52. PubMed ID: 28741234
    [No Abstract]   [Full Text] [Related]  

  • 2. Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature.
    Dufrost V; Risse J; Zuily S; Wahl D
    Curr Rheumatol Rep; 2016 Dec; 18(12):74. PubMed ID: 27812956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature: Comment.
    Cohen H; Hunt BJ; Efthymiou M; Mackie IJ; Khamashta M; Isenberg DA;
    Curr Rheumatol Rep; 2017 Aug; 19(8):50. PubMed ID: 28730526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis.
    Dufrost V; Risse J; Reshetnyak T; Satybaldyeva M; Du Y; Yan XX; Salta S; Gerotziafas G; Jing ZC; Elalamy I; Wahl D; Zuily S
    Autoimmun Rev; 2018 Oct; 17(10):1011-1021. PubMed ID: 30103045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing APLS and oranges: caution with the use of direct-acting oral anticoagulants (DOACs) instead of warfarin in the treatment of antiphospholipid syndrome (APLS).
    Benger M; Vink J; Snell LB; Breen K
    BMJ Case Rep; 2019 Apr; 12(4):. PubMed ID: 30940667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct-acting oral anticoagulants in antiphospholipid syndrome: A systematic review.
    Girón-Ortega JA; Girón-González JA
    Med Clin (Barc); 2023 Jul; 161(2):65-77. PubMed ID: 37105842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrent Thrombosis in Patients with Antiphospholipid Syndrome Receiving Newer Oral Anticoagulants: A Case Report and Review of Literature.
    Joshi A; Hong J; Siva C
    Clin Med Res; 2017 Jun; 15(1-2):41-44. PubMed ID: 28751467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct oral anticoagulants versus warfarin in patients with single or double antibody-positive antiphospholipid syndrome.
    Williams B; Saseen JJ; Trujillo T; Palkimas S
    J Thromb Thrombolysis; 2022 Jul; 54(1):67-73. PubMed ID: 34817786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE.
    Cohen H; Doré CJ; Clawson S; Hunt BJ; Isenberg D; Khamashta M; Muirhead N;
    Lupus; 2015 Sep; 24(10):1087-94. PubMed ID: 25940537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome.
    Pengo V; Denas G; Zoppellaro G; Jose SP; Hoxha A; Ruffatti A; Andreoli L; Tincani A; Cenci C; Prisco D; Fierro T; Gresele P; Cafolla A; De Micheli V; Ghirarduzzi A; Tosetto A; Falanga A; Martinelli I; Testa S; Barcellona D; Gerosa M; Banzato A
    Blood; 2018 Sep; 132(13):1365-1371. PubMed ID: 30002145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial.
    Cohen H; Hunt BJ; Efthymiou M; Arachchillage DR; Mackie IJ; Clawson S; Sylvestre Y; Machin SJ; Bertolaccini ML; Ruiz-Castellano M; Muirhead N; Doré CJ; Khamashta M; Isenberg DA;
    Lancet Haematol; 2016 Sep; 3(9):e426-36. PubMed ID: 27570089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two-year outcomes after the study closure.
    Pengo V; Hoxha A; Andreoli L; Tincani A; Silvestri E; Prisco D; Fierro T; Gresele P; Cafolla A; De Micheli V; Ghirarduzzi A; Tosetto A; Falanga A; Martinelli I; Testa S; Barcellona D; Gerosa M; Denas G
    J Thromb Haemost; 2021 Feb; 19(2):531-535. PubMed ID: 33128325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct oral anticoagulants: an alternative treatment for thrombotic antiphospholipid syndrome?
    Resseguier AS; Pereira B; Rieu V; Le Guenno G; Grobost V; Ruivard M
    Lupus; 2017 Oct; 26(12):1297-1303. PubMed ID: 28355988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct oral anticoagulants versus warfarin in patients with antiphospholipid syndrome: A meta-analysis of randomized controlled trials.
    Lee YH; Song GG
    Lupus; 2022 Oct; 31(11):1335-1343. PubMed ID: 35968627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrent venous thrombosis despite 'optimal anticoagulation therapy' for antiphospholipid syndrome--could new oral anticoagulants solve the problem?
    Balaban M; Stanrić V; Rincić G; Ledinsky M; Grbac L; Stancić N; Tomasić H
    Acta Clin Croat; 2010 Dec; 49(4):469-77. PubMed ID: 21830460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombin Generation in a patient with Triple Positive Antiphospholipid Syndrome Treated with Three Different Anticoagulants.
    Bergstrom CP; Zia A; Sarode R; Nagalla S
    Transfus Apher Sci; 2020 Oct; 59(5):102815. PubMed ID: 32507383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial.
    Pengo V; Banzato A; Bison E; Zoppellaro G; Padayattil Jose S; Denas G
    Lupus; 2016 Mar; 25(3):301-6. PubMed ID: 26466613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of antiphospholipid antibody syndrome: a systematic review.
    Lim W; Crowther MA; Eikelboom JW
    JAMA; 2006 Mar; 295(9):1050-7. PubMed ID: 16507806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of direct oral anticoagulants in antiphospholipid syndrome.
    Cohen H; Efthymiou M; Isenberg DA
    J Thromb Haemost; 2018 Jun; 16(6):1028-1039. PubMed ID: 29624847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rivaroxaban limits complement activation compared with warfarin in antiphospholipid syndrome patients with venous thromboembolism.
    Arachchillage DR; Mackie IJ; Efthymiou M; Chitolie A; Hunt BJ; Isenberg DA; Khamashta M; Machin SJ; Cohen H
    J Thromb Haemost; 2016 Nov; 14(11):2177-2186. PubMed ID: 27541499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.